This Article Full Text Full Text (PDF) All Versions of this Article: 39/3/1042    most recent STROKEAHA.107.501361v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nassief, A. Articles by Marsh, J. D. Search for Related Content PubMed PubMed Citation Articles by Nassief, A. Articles by Marsh, J. D. Related Collections Primary prevention Secondary prevention

(Stroke. 2008;39:1042.)
© 2008 American Heart Association, Inc.

Comments, Opinions, and Reviews

Statin Therapy for Stroke Prevention

From the Washington University School of Medicine (A.N.), Saint Louis, Mo; and the University of Arkansas for Medical Sciences (J.D.M.), Little Rock.

Correspondence to James D. Marsh, MD, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St. # 832, Little Rock, AR 72205. E-mail jdmarsh{at}uams.edu

Background and Purpose— Statins are widely used to reduce the risk of stroke in patients with coronary artery disease (CAD), but less so in patients without CAD. We reviewed recent trials for new evidence for the reduction in risk of stroke.

Summary of Review— In patients with CAD, moderate-intensity statin treatment has been associated with reductions in risk of stroke, with no increase in hemorrhagic stroke. Additionally, in the TNT trial, intensive lipid lowering provided further stroke risk reduction compared with moderate lipid lowering in patients with stable CAD. Evidence is now available that statin therapy also reduces stroke risk in patients without CAD but at high cardiovascular risk, or with diabetes mellitus. The SPARCL trial showed that intensive statin therapy started within 6 months after a cerebrovascular event significantly reduced stroke risk and stroke severity. Low cholesterol levels have been associated with increased risk of hemorrhagic stroke, but although an increased risk of hemorrhagic stroke was observed in patients with prior hemorrhagic stroke in SPARCL, this was not related to low-density lipoprotein cholesterol levels. Clinical trials have recruited few patients with both coronary and cerebrovascular disease, but these patients are also expected to experience significant cardiovascular benefit with statin therapy.

Conclusions— Trial data show that statins reduce the risk of stroke, in addition to providing cardiovascular benefits. Consequently, physicians should consider statin therapy in all patients at high risk of stroke.

Key Words: cerebrovascular accident • coronary artery disease • statins • cholesterol

This article has been cited by other articles:

				J. Z. Willey, Q. Xu, B. Boden-Albala, M. C. Paik, Y. P. Moon, R. L. Sacco, and M. S. V. Elkind Lipid Profile Components and Risk of Ischemic Stroke: The Northern Manhattan Study (NOMAS) Arch Neurol, November 1, 2009; 66(11): 1400 - 1406. [Abstract] [Full Text] [PDF]

				V. Prinz and M. Endres The Acute (Cerebro)Vascular Effects of Statins Anesth. Analg., August 1, 2009; 109(2): 572 - 584. [Abstract] [Full Text] [PDF]

				H. J. Milionis, S. Giannopoulos, M. Kosmidou, V. Panoulas, E. Manios, A. P. Kyritsis, M. S. Elisaf, and K. Vemmos Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival Neurology, May 26, 2009; 72(21): 1816 - 1822. [Abstract] [Full Text] [PDF]